This company listing is no longer active
Oncolytics Biotech (ONC) Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ONC Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Oncolytics Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.42 |
| 52 Week High | CA$2.08 |
| 52 Week Low | CA$0.45 |
| Beta | 1.48 |
| 1 Month Change | -2.07% |
| 3 Month Change | 173.08% |
| 1 Year Change | 9.23% |
| 3 Year Change | -22.83% |
| 5 Year Change | -37.44% |
| Change since IPO | -90.04% |
Recent News & Updates
Recent updates
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
Aug 10
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?
Jan 28We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Feb 23Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Jul 07Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Mar 24Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?
Dec 09We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate
Aug 25Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
May 12We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Dec 02We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Aug 05Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth
Apr 15We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Dec 31Shareholder Returns
| ONC | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 3.6% | 1.3% | 1.1% |
| 1Y | 9.2% | 11.7% | 20.4% |
Return vs Industry: ONC underperformed the Canadian Biotechs industry which returned 17.7% over the past year.
Return vs Market: ONC underperformed the Canadian Market which returned 17.7% over the past year.
Price Volatility
| ONC volatility | |
|---|---|
| ONC Average Weekly Movement | 19.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: ONC's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: ONC's weekly volatility has increased from 14% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 28 | Jared Kelly | oncolyticsbiotech.com |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Oncolytics Biotech Inc. Fundamentals Summary
| ONC fundamental statistics | |
|---|---|
| Market cap | CA$142.51m |
| Earnings (TTM) | -CA$30.41m |
| Revenue (TTM) | n/a |
Is ONC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONC income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$30.41m |
| Earnings | -CA$30.41m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ONC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/26 12:42 |
| End of Day Share Price | 2025/08/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncolytics Biotech Inc. is covered by 23 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Byron Capital Markets |
| Douglas Loe | Cantor Fitzgerald Canada Corporation |
| Douglas Loe | Echelon Wealth Partners Inc. |